Akademik Veri Yönetim Sistemi
Journal of Food Measurement and Characterization, cilt.18, sa.1, ss.593-603, 2024 (SCI-Expanded)
Exemestane, a key drug in the treatment of breast cancer, must be accurately detected in order to evaluate patient response and improve therapeutic approaches. This study focuses on the creation of a sensitive exemestane detection technology, illustrating its potential for accurate drug level monitoring in clinical settings. The purpose of this study was to create Ag nanoparticles that were anchored onto a reduced-graphene-oxide (rGO) modified glassy-carbon electrode (Ag-rGO/GCE) for the sensitive detection of exemestane (EXE) as a breast cancer medication. X-ray diffractometer (XRD), scanning electron microscope (SEM), and X-ray photoelectron spectroscopy (XPS) structural and morphological analyses revealed that Ag nanoparticles ornamented rGO nanosheets. Electrochemical investigations employing electrochemical impedance spectroscopy (EIS), cyclic voltammetry (CV), and amperometry analyses revealed that the Ag-rGO/GCE has a better electron transfer ability and a high sensitivity and selectivity towards EXE. The sensor has a linear range of 10 to 750 µg/mL, a sensitivity value of 0.5330 µA/µg.m− 1, and a limit of detection (LOD) of 2.8 ng/mL, according to the results. Using blood serum, tap water and agricultural wastewater samples to assess the performance of the proposed sensor for detecting EXE, the sensor demonstrated significant recovery values (exceeding 95.00%) and good precision (with a relative standard deviation of less than 4.75%). These data effectively confirmed the Ag-rGO/GCE sensor’s dependability and precision in monitoring EXE levels in serum and water source samples for clinical and environmental analyses.